Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $33.28 USD
Change Today 0.00 / 0.00%
Volume 0.0
ACOR On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 03/31/15 All times are local (Market data is delayed by at least 15 minutes).

acorda therapeutics inc (ACOR) Snapshot

Open
$33.67
Previous Close
$33.28
Day High
$34.07
Day Low
$33.22
52 Week High
01/13/15 - $45.45
52 Week Low
08/1/14 - $28.26
Market Cap
1.4B
Average Volume 10 Days
679.2K
EPS TTM
$0.69
Shares Outstanding
42.6M
EX-Date
--
P/E TM
48.4x
Dividend
--
Dividend Yield
--
Current Stock Chart for ACORDA THERAPEUTICS INC (ACOR)

acorda therapeutics inc (ACOR) Related Businessweek News

No Related Businessweek News Found

acorda therapeutics inc (ACOR) Details

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes novel therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with multiple sclerosis (MS); Zanaflex Capsules and Zanaflex tablets for the management of spasticity, a symptom of central nervous system disorders; and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. The company also markets Ampyra as Fampyra in Europe, Asia, and the Americas. It is also involved in developing CVT-301, which is in Phase III clinical trial for the treatment of OFF episodes in Parkinson’s disease; Dalfampridine that is in Phase III clinical trial for the treatment of chronic post-stroke deficits; Neuregulin Program, which is in Phase Ib clinical trial for the treatment of heart failure; CVT-427 that is in pre-clinical development for the treatment of migraines; Remyelinating Antibodies Program, which is in Phase I clinical trial for the treatment of MS; and Chondroitinase Program that is in research stage for the treatment of spinal cord injury, as well as developing Plumiaz, a proprietary nasal spray formulation of diazepam for the treatment of people with epilepsy. The company has a collaboration agreement with Biogen Idec International GmbH for the development and commercialization of products containing aminopyridines. The company was founded in 1995 and is headquartered in Ardsley, New York.

489 Employees
Last Reported Date: 02/27/15
Founded in 1995

acorda therapeutics inc (ACOR) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $720.8K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $193.9K
Chief of Business Operations
Total Annual Compensation: $312.7K
General Counsel, Corporate Secretary and Pres...
Total Annual Compensation: $517.7K
Chief Medical Officer
Total Annual Compensation: $418.5K
Compensation as of Fiscal Year 2013.

acorda therapeutics inc (ACOR) Key Developments

Acorda Therapeutics, Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-24-2015 11:00 AM

Acorda Therapeutics, Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-24-2015 11:00 AM. Venue: The New York Palace Hotel, New York, New York, United States. Speakers: Ron Cohen, Founder, Chief Executive Officer, President and Director.

Acorda Therapeutics, Inc. Announces Unaudited Consolidated Financial Results for the Fourth Quarter and Full Year Ended December 31, 2014; Reports Asset Impairment for the Fourth Quarter Ended December 31, 2014

Acorda Therapeutics, Inc. announced unaudited consolidated financial results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported net income of $0.3 million, or $0.01 per diluted share against net income in the same quarter of 2013 was $6.2 million, or $0.15 per diluted share a year ago. Non-GAAP net income was $19.7 million, or $0.46 per diluted share against non-GAAP net income of $18.9 million, or $0.45 per diluted share a year ago. Total Revenue was $117.872 million against $92.593 million a year ago. Operating income was $1.169 million against $12.749 million a year ago. Loss before income taxes was $2.693 million compared to income before income taxes of $12.630 million a year ago. For the full year, the company reported net income of $17.7 million, or $0.42 per diluted share against net income for the full year 2013 was $16.4 million, or $0.39 per diluted share a year ago. Non-GAAP net income was $73.8 million, or $1.74 per diluted share against non-GAAP net income for the full year ended December 31, 2013 of $52.4 million, or $1.26 per diluted share. Total revenues were $401.480 million against $336.430 million a year ago. Operating income was $36.391 million against $30.365 million a year ago. Income before income taxes was $28.009 million compared to $28.863 million a year ago. For the fourth quarter ended December 31, 2014. the company reported asset impairment of $6.991 million.

Acorda Therapeutics, Inc. Presents at Barclays Global Healthcare Conference, Mar-11-2015 01:35 PM

Acorda Therapeutics, Inc. Presents at Barclays Global Healthcare Conference, Mar-11-2015 01:35 PM. Venue: Loews Miami Beach Hotel, 1601 Collins Avenue, Miami, Florida, United States. Speakers: Michael W. Rogers, Chief Financial Officer and Principal Accounting Officer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACOR:US $33.28 USD 0.00

ACOR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ACADIA Pharmaceuticals Inc $32.59 USD 0.00
Depomed Inc $22.41 USD 0.00
Durect Corp $1.91 USD 0.00
Impax Laboratories Inc $46.87 USD 0.00
Isis Pharmaceuticals Inc $63.67 USD 0.00
View Industry Companies
 

Industry Analysis

ACOR

Industry Average

Valuation ACOR Industry Range
Price/Earnings 81.6x
Price/Sales 3.5x
Price/Book 2.6x
Price/Cash Flow 81.7x
TEV/Sales 2.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACORDA THERAPEUTICS INC, please visit www.acorda.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.